USNA at a glance
USANA HEALTH SCIENCES INC (USNA, SEC CIK 896264) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended January 3, 2026 (FY2025), USANA HEALTH SCIENCES INC (USNA) reported revenue of $925.3 million (up 8.3% from FY2024) and net income of $10.8 million. Diluted EPS was $0.58.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding USANA HEALTH SCIENCES INC (USNA) shares worth $81.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $925.3M
- +8.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $81.1M · +0 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Oct 3, 2026
Management Discussion & Analysis
- Q3 revenue $205.9M, down 3.6% YoY from $213.7M
- Consolidated gross margin 76.3% vs 77.2% YoY, operating margin (0.7%) vs 0.6%
- Best segment: Hiya revenue $31.5M, up 2.3%; worst: Rise revenue $3.6M, down 44.8%
- Cash $178.9M vs $158.4M, operating cash flow $45.0M, financing outflows $17.8M
- Headwinds: active Customers down 8.2%, challenging customer acquisition, Hiya digital marketing pressure in early 2026
Risk Factors
- No explicit 10-Q risk-factor changes disclosed, limiting assessment of newly added risks
- Hiya impairment risk: lower-than-expected performance and forecast changes triggered a $29,137 goodwill charge
- Credit covenant risk: amended minimum EBITDA threshold reduced to $70,000 when revolving exposure stays below $50,000
- Near-term operating risk: Hiya and Rise generated operating losses of $6,336 and $2,055 in the third quarter
- Foreign-exchange risk: 2026 net-investment hedge carried a $61,766 notional amount
AI summary of the USNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- USANA reported third-quarter fiscal 2026 results for the period ended October 3, 2026
- Management Commentary provides additional operating context through Exhibit 99.2
Item 7.01: Regulation FD Disclosure
- Item 7.01 incorporates the Item 2.02 disclosure and Item 9.01 exhibits
- Investor significance depends on the earnings information and supporting exhibits referenced elsewhere in the filing
Item EX-99.2: Item EX-99.2
- Q3 net sales $206M, down 4% year over year, with Core Nutritional and Rise declines outweighing Hiya growth
- Net loss $5.6M, diluted EPS $(0.30), and Adjusted EBITDA $12.1M, down 13% year over year
Item EX-99.1: Item EX-99.1
- Q3 net sales $206M, down 4% year over year, with Core Nutritional and Rise declines outweighing Hiya growth
- Net loss $(5.6)M and diluted EPS $(0.30), while adjusted EBITDA fell 13% to $12.1M
Item 2.03: Creation of a Direct Financial Obligation
- $75 million revolving credit facility extended to June 27, 2030, with potential increases up to $200 million
- New minimum trailing-four-quarter EBITDA covenant: $100 million, reduced to $70 million when lender exposure is $50 million or less
Item 7.01: Regulation FD Disclosure
- Item 7.01 incorporates the Item 2.02 earnings disclosure and Item 9.01 exhibits
- Investor focus remains the company’s reported fiscal 2026 results and accompanying materials
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results released for quarter ended July 4, 2026
- Management Commentary furnished as Exhibit 99.2 for financial and operating details
Item EX-99.1: Item EX-99.1
- Q2 net sales fell 5% to $223 million, while adjusted EBITDA attributable to USANA declined 9% to $27.8 million
- $29.1 million preliminary non-cash Hiya goodwill impairment drove a $21.4 million net loss and $(1.16) diluted EPS
AI summaries of USNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for USNA
Don't miss the next USNA filing
- Alerts as it files. A push when USNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut USNA, by share count.
- Ask anything. An AI agent that reads every USNA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Nixon J Scott | M | Oct 22, 2026 | 1,632 | - |
| Ding Xia | M | Oct 22, 2026 | 1,632 | - |
| Pelosi Peggie | M | Oct 22, 2026 | 1,632 | - |
| Pelosi Peggie | M | Oct 22, 2026 | 1,632 | - |
| Ding Xia | M | Oct 22, 2026 | 1,632 | - |
| Ding Xia | F | Oct 22, 2026 | 604 | $14.52 |
| Fleming John Turman | M | Oct 22, 2026 | 1,632 | - |
| Fleming John Turman | M | Oct 22, 2026 | 1,632 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $854.5M | $925.3M |
| Gross Profit | - | $693.3M | $724.4M |
| Operating Income | - | $66.3M | $37.4M |
| Net Income | - | $42.0M | $10.8M |
| Gross Margin | - | 81.1% | 78.3% |
| Op. Margin | - | 7.8% | 4.0% |
| Net Margin | - | 4.9% | 1.2% |
| Balance Sheet | |||
| Total Assets | $632.8M | $748.2M | $742.9M |
| Equity | $497.2M | $532.1M | $533.1M |
| ROE | - | 7.9% | 2.0% |
| Per Share | |||
| EPS | - | $2.19 | $0.58 |
| Cash Flow | |||
| Operating CF | - | $61.0M | $22.3M |
| CapEx | - | $10.1M | $13.8M |
Source: XBRL data in USANA HEALTH SCIENCES INC (USNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate USNA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $81.1M |
| Q2 2026 | 25 | $125.3M |
| Q1 2026 | 25 | $94.9M |
| Q4 2025 | 24 | $114.8M |
| Q3 2025 | 28 | $189.9M |
| Q2 2025 | 29 | $210.5M |
| Q1 2025 | 25 | $140.1M |
| Q4 2024 | 21 | $170.6M |
- Morgan Stanley+67.2K (+41%)
- Goldman Sachs Group+34.2K (+28%)
- JPMorgan Chase & Co+25.7K (+463%)
- Citigroup+16.2K (+97%)
- Millennium Management+11.5K (+43%)
- AQR Capital Management−331.2K (-81%)
- BlackRock−117.0K (-8%)
- Bank of America Corp−21.3K (-47%)
- Dimensional Fund Advisors−17.6K (-2%)
- State Street Corp−17.0K (-6%)
- Prudential Financial+65.2K
- Mangrove Partners+18.8K
- FMR LLC (Fidelity)−5.8K
- U.S. Bancorp−27
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
USNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Oct 3, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 4 | Oct 23, 2026 | - | - | - |
| 8-K | Oct 5, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jul 4, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - |
Related Health Care companies
- BTMD · biote Corp.Medicinal Chemicals & Botanical Products
- DFTX · Definium Therapeutics, Inc.Medicinal Chemicals & Botanical Products
- FTLF · FITLIFE BRANDS, INC.Medicinal Chemicals & Botanical Products
- MDWD · MediWound Ltd.Medicinal Chemicals & Botanical Products
- NAGE · Niagen Bioscience, Inc.Medicinal Chemicals & Botanical Products
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
USNA SEC filings: frequently asked questions
Which institutions hold USNA stock?
As of September 30, 2026, the largest USANA HEALTH SCIENCES INC (USNA) holders among the 13F filers tracked by SignalX were BlackRock ($20.8 million), Renaissance Technologies LLC ($14.0 million), Dimensional Fund Advisors ($11.9 million), Vanguard Capital Management LLC ($7.1 million), Vanguard Portfolio Management LLC ($5.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was USNA's revenue in fiscal year 2025?
For the fiscal year ended January 3, 2026 (FY2025), USANA HEALTH SCIENCES INC (USNA) reported revenue of $925.3 million (up 8.3% from FY2024) and net income of $10.8 million. Diluted EPS was $0.58. The figures come from the XBRL data in the 10-K.
What did USNA report in its latest 8-K?
USANA HEALTH SCIENCES INC (USNA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). USANA reported third-quarter fiscal 2026 results for the period ended October 3, 2026.
What are the latest USNA SEC filings?
USANA HEALTH SCIENCES INC (USNA) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 23, 2026.
What is USNA's SEC CIK number?
USANA HEALTH SCIENCES INC (USNA)'s SEC Central Index Key (CIK) is 896264. EDGAR lists every USNA filing under that number.
Ask anything about USNA
The research agent reads USNA's filings, financials, insider trades and 13F holders, then answers with sources.